Susan M van Dommelen1, Roy van der Meel1,2, Wouter W van Solinge1, Maria Coimbra3, Pieter Vader1, Raymond M Schiffelers1. 1. Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. 2. Department of Biochemistry & Molecular Biology, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. 3. Department of Pharmaceutics, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
Abstract
AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR). MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting. RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs. CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.
AIM: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR). MATERIALS & METHODS: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting. RESULTS: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs. CONCLUSION: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.
Entities:
Keywords:
EGFR; biomarker; cancer therapy; cetuximab; diagnostics; exosomes; extracellular vesicles
Authors: Thomas Simon; Sotiria Pinioti; Pascale Schellenberger; Vinothini Rajeeve; Franz Wendler; Pedro R Cutillas; Alice King; Justin Stebbing; Georgios Giamas Journal: Mol Cancer Date: 2018-08-31 Impact factor: 27.401